Aerovate Therapeutics Emerges From Ra Capital Incubator With $72.6M Funding For Potential Disease-modifying Pulmonary Arterial Hypertension Therapy

by vcaonline.com posted 12months ago 208 views
Aerovate Therapeutics Emerges From RA Capital Incubator With $72.6 Million Funding for Potential Disease-Modifying Pulmonary Arterial Hypertension Therapy AV-101 is a Proprietary Inhaled Version of Imatinib, Which Has Proven Efficacy Treating PAH; Aerovate Was Founded and Seeded by RA Capital Management; Series A is Led by Sofinnova Investments; Includes New Investors Atlas Venture, Cormorant Asset Management, Surveyor Capital and Osage University Partners BOSTON, August 6, 2020-- Aerovate Therapeutics, Inc., has closed on $72.6 million in Series A funding to advance trials of AV-101, an inhaled, dry powder aerosol version of imatinib to treat pulmonary arterial hypertension (PAH).

In this article